Press Releases

22 Nov 2016.
MedReleaf, Canada's premium licensed producer of medical cannabis, today announced the findings from a landmark study on the effectiveness of medical cannabis on military veterans diagnosed with PTSD. The study found treatment with medical cannabis improved aggregate patient reported outcomes by 50-60% with a 77% decrease in suicidal thoughts as well as a 50% reduction in the consumption of related medications. The study, being presented today in Vancouver at the 7th Annual Military and Veteran Health Research Forum, was conducted by Dr. Paul Smith, MD, using several of MedReleaf's proprietary strains of medical cannabis including AviDekel, Luminarium and Midnight. From baseline to follow up, the study revealed a number of key insights on patient outcomes including: Aggregate score of both PTSD symptoms and social impacts improved by 59% Drug and alcohol overuse was reduced by 82% Marital and relationship harmony improved 65% and Severity of pain experienced by patients decreased ...
8 Nov 2016.
MedReleaf, Canada's leading medical cannabis licensed producer, today announced it has become the first licensed producer (LP) to bring cannabis capsules to market. This news follows on recent Health Canada approval for MedReleaf to begin selling both cannabis oils and capsules. Capsules provide access to cannabis for an under-served patient community who are more comfortable taking their medication in traditional capsule form rather than by oil or through vapourizers. For patients and physicians alike, capsules also provide increased confidence and comfort in regard to precise dosing. Securing approval on easy-to-use capsules provides further evidence of MedReleaf's position as the leader in the field of medical grade cannabis and its commitment to scientific advancement in the industry.  "MedReleaf is committed to being a leader in cannabis research and development as well as in best understanding patient needs," noted Neil Closner, MedReleaf's CEO.  "Our initial and ...